Head and Neck Squamous Cell Carcinoma Clinical Trials
65 studies are recruiting for head and neck squamous cell carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
By city
Studies, page 3
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibit…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- St Vincent's Hospital, Darlinghurst, New South Wales
- Locations
- 16 in total
- Run by
- OncoNano Medicine, Inc.
-
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…
- Stage
- Phase 1
- Ages
- 18 to 80
- Site
- Providence Medical Foundation (site 209), Santa Rosa, California
- Locations
- 15 in total
- Run by
- VM Oncology, LLC
-
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
The goal of this clinical trial is to compare the effectiveness of a navigation-based multilevel intervention (ENDURE) with treatment as usual (TAU) to improve the initiation of guideline-adherent postoperative radiation therapy among patients with head and neck cancer. The main questions the trial…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Washington University in St. Louis, St Louis, Missouri
- Locations
- 4 in total
- Run by
- Medical University of South Carolina
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer. How well they do isn't as related to the kinds of treatment they get. However, there are significant side …
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Maryland Proton Treatment Center, Baltimore, Maryland
- Locations
- 5 in total
- Run by
- University of Maryland, Baltimore
-
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Southern California, Los Angeles, California
- Locations
- 14 in total
- Run by
- Volastra Therapeutics, Inc.
-
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
This early phase I trial compares sodium fluoride F-18 (F-18 NaF) positron emission tomography (PET)/computed tomography (CT) to the standard of care imaging scan (and fludeoxyglucose F-18 [F-18 FDG] PET/CT) for assessing the effects radiation therapy has on the blood vessels in the neck in patient…
- Stage
- EARLY_Phase 1
- Ages
- 18 and older
- Site
- Emory University Hospital Midtown, Atlanta, Georgia
- Run by
- Emory University
-
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
The purpose of the study is to determine the activity and safety of ACR-368 (prexasertib) in combination with gemcitabine in participants with Head and Neck Squamous Cell Carcinoma (HNSCC). Participants will receive the study drugs ACR-368 and a low dose of gemcitabine once every 2 weeks in 4-week …
- Stage
- Phase 2
- Ages
- 18 and older
- Site
- Moffitt Cancer Center, Tampa, Florida
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
-
Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer
This phase I trial evaluates the safety and effectiveness of using two imaging techniques, indium In 111 panitumumab (111In-panitumumab) with single photon emission computed tomography (SPECT)/computed tomography (CT) and panitumumab-IRDye800 fluorescence imaging during surgery (intraoperative), to…
- Stage
- Phase 1
- Ages
- 19 and older
- Site
- Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
- Run by
- Vanderbilt-Ingram Cancer Center
-
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- University of Southern California, Los Angeles, California
- Locations
- 17 in total
- Run by
- Nurix Therapeutics, Inc.
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Moores Cancer Center UC San Diego Health, La Jolla, California
- Locations
- 20 in total
- Run by
- Bicara Therapeutics
-
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in microdose quantities via the CIVO device.
- Stage
- EARLY_Phase 1
- Ages
- 18 and older
- Site
- LSU Health Sciences Center, Shreveport, Louisiana
- Run by
- Pure Biologics S.A.
-
Evaluation of Radiobiological Effects in Skin Toxicities Head and Neck Cancer Patients With PBS Proton Therapy
This purpose of this study is to examine skin reactions (called radiation dermatitis) that occur during pencil beam scanning (PBS) proton therapy. The researchers will test a unique technique called "Spot Delete" to see if it can reduce skin reactions for head \& neck patients treated with PBS. The…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Thompson Proton Center, Knoxville, Tennessee
- Run by
- Covenant Health Cancer Center
-
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
This study consists of phase 1b and 2a to evaluate safety, Pharmacokinetics, and efficacy of TU2218 in combination with Pembrolizumab in patients with advanced solid tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- CHA University Bundang Medical Center, Seongnam,
- Locations
- 11 in total
- Run by
- TiumBio Co., Ltd.
-
Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
This is a phase 2, single-arm, open-label clinical trial determining safety and tolerability of AHCC in subjects with HPV-positive patients with Head and Neck Squamous Cell Carcinoma. These are subjects who have undergone surgery or will be undergoing surgery.
- Stage
- Phase 2
- Ages
- 18 to 79
- Site
- Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
- Run by
- University of California, Irvine
-
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
- Stage
- EARLY_Phase 1
- Ages
- 18 and older
- Site
- Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
- Run by
- Vanderbilt-Ingram Cancer Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.